An open label, phase II multicentre evaluation of the activity and safety of fotemustine administered to patients with recurrent or progressive glioblastoma multiforme.
Latest Information Update: 12 Jul 2011
At a glance
- Drugs Fotemustine (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Italfarmaco
- 21 Jun 2011 New trial record